---
title: "Sanofi (SNY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SNY.US.md"
symbol: "SNY.US"
name: "Sanofi"
industry: "Pharmaceuticals"
datetime: "2026-05-19T15:00:10.410Z"
locales:
  - [en](https://longbridge.com/en/quote/SNY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SNY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SNY.US.md)
---

# Sanofi (SNY.US)

## Company Overview

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.sanofi.com](https://www.sanofi.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 40 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.73% |  |
| Net Profit YoY | 30.10% |  |
| P/B Ratio | 1.25 |  |
| Dividend Ratio | 4.06% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 104515167091.72 |  |
| Revenue | 55313938921.68 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.00% | D |
| Profit Margin | 0.00% | D |
| Gross Margin | 72.09% | A |
| Revenue YoY | 13.73% | B |
| Net Profit YoY | 30.10% | B |
| Total Assets YoY | 2.76% | C |
| Net Assets YoY | 4.05% | C |
| Cash Flow Margin | 136.86% | B |
| OCF YoY | 13.73% | B |
| Turnover | 0.00 | E |
| Gearing Ratio | 42.87% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Sanofi",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "30.10%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.25",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "4.06%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "104515167091.72",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "55313938921.68",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "72.09%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.73%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "30.10%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.76%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.05%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "136.86%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "13.73%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.87%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 11.84 | 15/190 | 17.11 | 12.10 | 11.56 |
| PB | 1.25 | 61/190 | 1.45 | 1.39 | 1.35 |
| PS (TTM) | 1.89 | 50/190 | 2.42 | 2.30 | 2.12 |
| Dividend Yield | 4.06% | 7/190 | 3.43% | 3.32% | 3.22% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 40% |
| Overweight | 1 | 10% |
| Hold | 5 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 43.62 |
| Highest Target | 63.00 |
| Lowest Target | 51.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SNY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SNY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SNY.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SNY.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**